Last reviewed · How we verify
Cergodum (NICERGOLINE)
Nicergoline works by increasing blood flow to the brain and improving cognitive function.
Cergodum, also known as Nicergoline, is a small molecule drug in the nicergoline class. It is used to treat certain conditions, although its exact target is unknown. The commercial status of Cergodum is unclear, and it may be patented or have generic manufacturers. Key safety considerations are not well-documented. Further research is needed to fully understand its effects and risks.
At a glance
| Generic name | NICERGOLINE |
|---|---|
| Drug class | nicergoline |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | discontinued |
Mechanism of action
Imagine your brain is a garden, and blood flow is like water nourishing the plants. Nicergoline helps to improve the flow of this water, allowing the brain to function better and potentially improving symptoms of certain conditions.
Approved indications
Common side effects
Key clinical trials
- Nicergoline Use in Dysphagia Patients (PHASE3)
- Exploring the Cognitive Benefits of a Blackcurrant-Based Supplement in Normobaric Hypoxia (NA)
- Effect of a Plant Based Nootropic on Perceptual Decision Making. (NA)
- An Bioequivalence Study Comparing Nicergoline 10 mg Tablet Manufactured in China With Nicergoline 10 mg Tablet Manufactured in Italy Under Fasted and Fed Conditions in Healthy Chinese Participants (PHASE1)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cergodum CI brief — competitive landscape report
- Cergodum updates RSS · CI watch RSS